Olink

Olink®
Part of Thermo Fisher Scientific

Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension

Nature Cardiovascular Research, 2022

Boucherat O., Yokokawa T., Krishna V., Kalyana-Sundaram S., Martineau S., Breuils-Bonnet S., Azhar N., Bonilla F., Gutstein D., Potus F., Lawrie A., Jeyaseelan J., Provencher S., Bonnet S.

Disease areaApplication areaSample typeProducts
CVD
Pathophysiology
Patient Stratification
Plasma
Olink Explore 3072/384

Olink Explore 3072/384

Abstract

Although right ventricular (RV) function is the primary determinant of morbidity and mortality in pulmonary arterial hypertension (PAH), the molecular mechanisms of RV remodeling and the circulating factors reflecting its function remain largely elusive. In this context, the identification of new molecular players implicated in maladaptive RV remodeling along with the optimization of risk stratification approaches in PAH are key priorities. Through combination of transcriptomic and proteomic profiling of RV tissues with plasma proteome profiling, we identified a panel of proteins, mainly related to cardiac fibrosis, similarly upregulated in the RV and plasma of patients with PAH with decompensated RV. Among these, we demonstrated that plasma latent transforming growth factor beta binding protein 2 (LTBP-2) level correlates with RV function in human PAH and adds incremental value to current risk stratification models to predict long-term survival in two independent PAH cohorts.

Read publication ↗